Eli Lilly’s late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.

By Sriparna Roy and Sahil Pandey April 16 (Reuters) - Eli Lilly said on Thursday its newly approved obesity pill was not ...

The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.

Eli Lilly's acquisition spree shows no sign of stalling, although the Big Pharma is keeping the terms of its latest buy ...

Can Eli Lilly (NYSE: LLY) stock surge 2x to $2,000 in the coming years? We believe that this is indeed a genuine possibility.

Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new ...

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

Eli Lilly just released results of a clinical trial that may ease concerns about the safety of its new weight-loss pill ...

With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 ...

By Sriparna Roy April 14 (Reuters) - The U.S. Food and Drug Administration has asked Eli Lilly for more data on liver injury ...

April 16 () - Eli Lilly said on Thursday its newly approved obesity ‌pill helped reduce the risk ‌of major cardiovascular ...